Genmab — Maj 2018

[Joakim_Von_And]

de mangler vist ikke noget

[E_L]

I dont know how they got to that 73k then earlier, but anyway, glad we can put this behind us again.

[jkj]

Asco abstrakts frigives i aften kl.23.00 er lidt i tvivl om late breaker er offentlig gjorte eller ej jf.https://am.asco.org/abstracts/abstract-policies-exceptions?qt-dynamic_tab_quicktabs=3#qt-dynamic_tab_quicktabs

[E_L]

I still find it amazing though how they allow the brokers to f*** them each time on the price... Surely there is a smarter way to sell your stock...

[Solsen]

The insider buy yesterday was surely not wise.

[E_L]

nope. she won't do that again

[E_L]

@jkj i am sort of hoping that someone will stay up tonight and will have a summary ready tomorrow morning (hint )

[Bulder]

LB abstracts bliver først offentliggjort under selve asco. Titlerne er dog kendte.

[E_L]

But Genmab doesnt have any LB abstracts this year..?

[Bulder]

no

[Bulder]

... and they only have one oral presentation: DKd

[E_L]

yeah... well , good news for @jkj , it will not take hime very long to make the summaries

[Solsen]

There could be very interesting abstracts from CAR-T and BCMA targets - duration is the main issue.

[Bulder]

ja, abstract 8007 skal nærlæses. Jeg har ikke kunnet finde GSK's bcma-adc.

[Bulder]

og så kan der jo være nyt fra Pavo-studiet. Kunne være herligt at få bekræftet at dara sc er mildere OG mere effektivt end IV.

[Solsen]

Ja det er et vigtigt studie. Hvis også vi kunne få bekræftet bedre effekt og mildere bivirkninger kunne det være super.

[Solsen]

Vi nærmer os stille og roligt store milestones,

[Solsen]

.

[Solsen]

Maia, solid, sc, MS etc

[Bulder]

Pavo: 44% ORR 2 % mere end på ASH. 28% VGPR, så det er i hvert fald ikke blevet dårligere.